1. Home
  2. ADPT vs PGY Comparison

ADPT vs PGY Comparison

Compare ADPT & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • PGY
  • Stock Information
  • Founded
  • ADPT 2009
  • PGY 2016
  • Country
  • ADPT United States
  • PGY United States
  • Employees
  • ADPT N/A
  • PGY N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • PGY Finance: Consumer Services
  • Sector
  • ADPT Health Care
  • PGY Finance
  • Exchange
  • ADPT Nasdaq
  • PGY Nasdaq
  • Market Cap
  • ADPT 1.1B
  • PGY 863.7M
  • IPO Year
  • ADPT 2019
  • PGY N/A
  • Fundamental
  • Price
  • ADPT $9.03
  • PGY $14.58
  • Analyst Decision
  • ADPT Buy
  • PGY Strong Buy
  • Analyst Count
  • ADPT 6
  • PGY 9
  • Target Price
  • ADPT $9.83
  • PGY $21.61
  • AVG Volume (30 Days)
  • ADPT 3.0M
  • PGY 1.9M
  • Earning Date
  • ADPT 05-01-2025
  • PGY 05-07-2025
  • Dividend Yield
  • ADPT N/A
  • PGY N/A
  • EPS Growth
  • ADPT N/A
  • PGY N/A
  • EPS
  • ADPT N/A
  • PGY N/A
  • Revenue
  • ADPT $189,527,000.00
  • PGY $1,076,961,000.00
  • Revenue This Year
  • ADPT $21.20
  • PGY $16.93
  • Revenue Next Year
  • ADPT $21.99
  • PGY $13.84
  • P/E Ratio
  • ADPT N/A
  • PGY N/A
  • Revenue Growth
  • ADPT 8.61
  • PGY 23.69
  • 52 Week Low
  • ADPT $2.99
  • PGY $8.20
  • 52 Week High
  • ADPT $10.28
  • PGY $19.20
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 57.82
  • PGY 71.79
  • Support Level
  • ADPT $8.38
  • PGY $10.68
  • Resistance Level
  • ADPT $9.51
  • PGY $12.05
  • Average True Range (ATR)
  • ADPT 0.66
  • PGY 0.83
  • MACD
  • ADPT 0.16
  • PGY 0.41
  • Stochastic Oscillator
  • ADPT 63.02
  • PGY 99.27

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.

Share on Social Networks: